Clinical Trial Update: 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of MK-3475 (pembrolizumab) combined with pomalidomide in relapsed/refractory multiple myeloma; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• MK-3475 (pembrolizumab)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Ashraf Badros | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-08-01